A Career Dedicated to Protecting Pregnant Mothers and Infants with Carol J. Baker, MD

10/04/23 • 33 min

In this episode, hosts Marla Dalton, PE, CAE, and William Schaffner, MD, talk with Carol J. Baker, MD, a leader in group B Streptococcus prevention and a passionate advocate for maternal immunization to help protect mothers and infants. She shares her perspectives on the most significant changes throughout her career, including the development of vaccines and antivirals as well as the inclusion of pregnant women in clinical trials for vaccines and drugs.
As a former competitive swimmer and now a daily walker, she has brought her energy and drive to national leadership positions, including as past president of NFID, as well as former chair of the Advisory Committee on Immunization Practices. NFID presented her with the John P. Utz Leadership Award in 2009 in recognition of her leadership and service to NFID and the field of infectious diseases. She was elected to the National Academy of Medicine in 2019.

Follow NFID on social media

Send us a text

Follow NFID on social media

Previous Episode

From HIV/AIDS to COVID - 19: Insights and Predictions with Rochelle P. Walensky, MD, MPH

Send us a text

In this episode, hosts Marla Dalton, PE, CAE, and William Schaffner, MD, talk with Rochelle P. Walensky, MD, MPH, former director of the Centers for Disease Control and Prevention (CDC), who was deeply involved in the responses to some of the biggest public health threats of the past 5 decades including HIV/AIDS and COVID-19. She shares her perspectives on the most significant changes she has seen throughout her career, how the HIV/AIDS epidemic helped shaped her work, the importance of rebuilding trust in CDC and other government agencies, and predictions for the upcoming respiratory season.

Follow NFID on social media

Next Episode

Operation Warp Speed: Transforming Disease Prevention with Peter Marks, MD, PhD

Send us a text

In this episode, hosts Marla Dalton, PE, CAE, and William Schaffner, MD, talk with Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration. He shares his insights on the origin of Operation Warp Speed during the COVID-19 pandemic, his efforts to transform the way that FDA approaches approval and licensure of new vaccines and other prevention tools, and his thoughts on how artificial intelligence may improve future work.
Show notes
Before joining FDA, Dr. Marks was clinical director of hematology at Brigham and Women's Hospital in Boston, MA. He worked in industry for several years on hematology and oncology drug development and then returned to academic medicine at Yale University where he led the Adult Leukemia Service and served as chief clinical officer of Smilow Cancer Hospital. He joined FDA in 2012 as CBER deputy director and became director in2016. In 2022, he became a member of the National Academy of Medicine. Born in Brooklyn, NY, the father of 2 grown children now lives with his wife in Washington, DC.

Follow NFID on social media